Current practices in the use of sildenafil for pulmonary arterial hypertension in Brazilian hospitals by de Souza, Ana HA et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Research Notes
Open Access Short Report
Current practices in the use of sildenafil for pulmonary arterial 
hypertension in Brazilian hospitals
Ana HA de Souza*1, Lucio M Cabral2 and Gisele Huf*3
Address: 1Pharmacy service, National Institute of Cardiology, Rio de Janeiro, Brazil, 2Pharmaceutical Industrial Tecnology Lab, Federal University 
of Rio de Janeiro, Rio de Janeiro, Brazil and 3National Institute of Quality Control in Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Email: Ana HA de Souza* - anahelena.aranda@gmail.com; Lucio M Cabral - lmcabral@pharma.ufrj.br; 
Gisele Huf* - gisele.huf@incqs.fiocruz.br
* Corresponding authors    
Abstract
Background:  Sildenafil is a cyclic guanosine monophosphate-specific  phosphodiesterase-5
inhibitor used for treating pulmonary hypertension. Although the use of sildenafil in patients under
18 years old is off-label, this inhibitor has been widely prescribed for children treatment at hospitals
in Brazil. In this work we evaluated the current practices in using sildenafil in the three main
reference hospitals of Rio de Janeiro to design a clinical trial. Then we analyzed the content of
sildenafil in powder paper preparations used in these institutions.
Methods and Results: We assessed the data about the use of sildenafil in three reference
hospitals including Instituto Nacional de Cardiologia – INC, Instituto Estadual de Cardiologia
Aloysio de Castro – IECAC and Hospital Pro-Cardíaco – HPC. The pharmacy records were
analyzed from April 1st, 2008 to April 30th, 2008 and interviews with the pharmacists were also
performed. Our results showed that INC used the greatest amount of sildenafil in: treatment of
pulmonary arterial hypertension (PAH), management of transient PAH during surgery, preparation
for cardiac transplantation and haemodynamic studies during cardiac catheterization. Meanwhile
IECAC and HPC used sildenafil only for treating PAH in few patients during the period evaluated.
In INC and IECAC, sildenafil was available in tablets, and powder papers prepared by two private
pharmacies and one public hospital pharmacy. In contrast all patients of HPC received sildenafil in
tablets with no external manipulation. Our quantification analysis results using reverse-phase high
performance liquid chromatography method showed that powder papers prepared by the private
pharmacies from the sildenafil tablets presented only 58.5 to 89.3% of the declared concentration
in contrast to samples from the public hospital pharmacy (104.4 to 105.3%).
Conclusion:  Few patients received the prescribed sildenafil dose at the reference hospitals
evaluated in Rio de Janeiro, which may importantly compromise this inhibitor effect in the current
treatment. This study reinforced the need of checking the practices of preparing and administering
sildenafil continually.
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Background
Sildenafil is a cyclic guanosine monophosphate-specific
phosphodiesterase-5 inhibitor used for the management
of pulmonary hypertension. According to the Brazilian
guidelines the dosage established for pulmonary arterial
hypertension (PAH) is 20 mg three times a day at the
beginning of the treatment and 0.3 mg/kg/day to 3 mg/
kg/day divided in three doses for pediatric patients [1].
Despite the existence of other treatment options such as
oral endothelin antagonists and prostacyclin analogues
(inhaled, subcutaneous or intravenous), they are not
available in Brazil due to the expensive cost [2].
Sildenafil might be an effective pulmonary vasodilator as
suggested by several case reports [3-6] and some trials in
children [7,8]. In most of these studies, the dose of silde-
nafil was 2 mg/kg every 6 hours. Sildenafil has also been
used during cardiac catheterization to evaluate the
haemodynamic deterioration and the vascular bed
response to pharmacologic stimuli. During this procedure
any degree of reversibility is searched, which provides
important prognostic information [9]. The haemody-
namic study is usually performed to identify children who
are responsive to vasodilators as a part of preoperative
assessment to congenital heart disease correction. Vasore-
active patients have a better long-term prognosis and are
more likely to respond favorably to the pharmacologic
treatment than non-responsive patients and children with
transient PAH during surgery. The Cochrane systematic
review about the use of sildenafil in adults suffering from
PAH showed that only four clinical trials with 77 partici-
pants met the inclusion criteria [10].
The Brazilian agency for drug regulation, the National
Agency of Sanitary Surveillance (ANVISA), released the
use of sildenafil for erectile disfunction in 1998 and PAH
treatment in 2006. In both cases the license was only
approved for patients above 18 years old in tablets with
25, 50 and 100 mg of sildenafil. Since it is the most avail-
able option in Brazil, it has been widely prescribed to
patients of all ages at Brazilian hospitals. The situation
leads to some problems as some inpatients (i.e. nasogas-
tric or nasoenteric tube-fed patients, those with altered
mental status, and small children) require treatment with
oral liquid dosage forms that are not frequently available.
In the absence of oral liquid dosage forms and to over-
come the swallowing problems, usually three practices are
performed at the Brazilian hospitals that include: cutting
sildenafil tablets into smaller segments (halves or quar-
ters), openning sildenafil capsules, and using sildenafil
injectable solutions for oral administration. It is also com-
mon the preparation of extemporaneous powders by
redistributing sildenafil from commercially available
crushed tablets or opened capsules into powder papers
(sachets) after using diluents (i.e. lactose).
Currently, the only advantage for children treatment using
sildenafil powder papers instead of tablets is the easier
swallowing process. However there are several limitations
involved in this use including:
• Errors during the preparation of the powder papers (i.e.
content homogeneity) especially when using crushed tab-
lets. A worse situation is noticed when, in the lack of the
powder papers, tablets are directly crushed by non-appro-
priate staff (i.e. nurses) for using on patients.
￿ Dose accuracy since sildenafil solubility in water is 1 mg/
3.5 ml and usually the powder paper is diluted in 5 ml of
water. Since the minimum amount of water to dilute one
powder paper containing 5 mg of sildenafil is 17.5 ml, prob-
ably part of the drug is not in solution, and the children are
not getting the entire drug amount that is necessary.
￿ Stability of the formulation that does not allow the drug
to be stored to posterior administration. On that matter,
there is a lack of stability studies of sildenafil powder
paper in water.
￿ Amount of water to dilute each powder paper to chil-
dren with water restriction (i.e. 17.5 ml of water to dilute
5 mg of sildenafil).
￿ Powder papers diluents (i.e.  lactose) that may cause
diarrhea, dehydration and metabolic acidosis in children
with lactose intolerance [11].
For all these reasons, studies about sildenafil should con-
sider the practices of preparing and administering this
drug. Therefore, in this work we evaluated the current
practices of using sildenafil in three main reference cardi-
ologic hospitals of Rio de Janeiro to design a clinical trial.
Then we analyzed the content of sildenafil present in the
powder paper used in these hospitals.
Methods
Rio de Janeiro has approximately 6 million habitants, and
two public reference cardiologic hospitals (Instituto
Nacional de Cardiologia-INC and Instituto Estadual de
Cardiologia Aloysio de Castro – IECAC), which are
responsible for attending 70% of the population, and a
private reference cardiologic hospital (Hospital Pro-
Cardíaco – HPC) that works only with private health
insurance patients. Our survey analyzed the pharmacy
records of these three reference hospitals searching for
everyone who had used sildenafil during the period of
April 1st, 2008 to April 30th, 2008. In this study, the main
pharmacist of each institution was also interviewed for
additional information about the use of sildenafil in clin-
ical conditions and drug preparation for children use. The
protocol of this study was approved by the Ethics Com-
mittee of Instituto Nacional de Cardiologia.BMC Research Notes 2009, 2:30 http://www.biomedcentral.com/1756-0500/2/30
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Since the preparation of the powder papers used by the
two public hospitals (INC and IECAC) was performed by
two private pharmacies and one public hospital phar-
macy, we collected five powder papers from each phar-
macy to be randomly selected and tested for quality
control. In this analysis, we used the reverse-phase high
performance liquid chromatography (HPLC) method
developed by Equifarma for quantification of sildenafil in
the powder papers. Briefly, the powder packs were diluted
with the mobile phase where for each powder paper, two
samples were produced and each sample was analyzed
twice. The HPLC column was a LiChrospher C18 (5 μm)
25 × 0.46 cm using the ammonium acetate 0.2 M pH
7.0:acetonitrile (1:1) as mobile phase. The injection vol-
umes were 20 μl and the flow rate was 1 ml/min. The col-
umn was monitored at 240 nm using a UV detector
wavelength.
Results
Instituto Nacional de Cardiologia (INC) – overview
Instituto Nacional de Cardiologia (INC) is a public insti-
tution for cardiac surgery located at Rio de Janeiro. In
2000, due to its services quality level, INC became a refer-
ence center for guidelines in cardiology area. Currently
INC is responsible for most of the pediatric cardiac surger-
ies of the state of Rio de Janeiro.
During the period of our evaluation, there were 5402
emergency attendances, 368 inpatients and 253 ambula-
torial attendances. Sildenafil has been used at INC since
December 2004 prescribed for treating pulmonary arterial
hypertension (PAH), restoring transient PAH during car-
diac surgery, cardiovascular stabilization to heart trans-
plantation and in haemodynamic study during cardiac
catheterization. Importantly, during 2005 and 2006 more
than 70 children had at least one prescription of sildena-
fil.
The usual dosage of sildenafil for treating PAH in pediatric
patients is 0.3 to 0.4 mg/kg/dose every 8 hours [12] and
0.2 mg/kg in haemodynamic study with cardiac catheteri-
zation. Since the hospital contains sildenafil in 25 mg-tab-
lets and considering the low weight of the children
eligible for the treatment and procedures, these tablets are
routinely sent to a private pharmacy to prepare 5 mg-
sildenafil powder papers. Then these powder papers are
sent to the nurses that add 5 ml of water and calculate the
required amount to be administered.
Instituto Estadual de Cardiologia Aloysio de Castro 
(IECAC) – overview
Instituto Estadual de Cardiologia Aloysio de Castro
(IECAC) is a reference state hospital that offers diagnosis
services and treatment for cardiovascular diseases. IECAC
is of great importance for the public health of Rio de
Janeiro state due to its high-qualified staff that treats dif-
ferent and complex cardiovascular disorders. During the
period of our evaluation, there were 3583 outpatients
attendances, 20 adult cardiac surgeries, 8 pediatric surger-
ies, 134 cardiac and vascular catheterizations and 834
imaging studies.
Similar to INC, sildenafil is also available at IECAC pre-
scribed to adults and children with PAH. In this hospital,
sildenafil tablets are also sent to a private pharmacy for
preparing 1 mg-sildenafil powder papers.
Hospital Pro-Cardíaco (HPC) – overview
Hospital Pro-Cardíaco (HPC) is a reference in cardiologic
assistance in Rio de Janeiro since the inauguration in
1959. During all these years, it has improved its perform-
ance by contracting different cardiac disorders specialists,
developing researches and using a technology comparable
to the best health centers in the world.
During the period of our evaluation there were 203 emer-
gency attendances with 136 inpatients admitted and no
outpatients attendances. Sildenafil is also prescribed to
adults and children in this hospital with no external
manipulation, different from the other two hospitals. In
fact sildenafil tablets are usually sent to the nurses in their
original packs.
Comparison of the use of sildenafil in children and adults 
in INC, IECAC and HPC
(see Additional file 1) shows that during the period of
evaluation, INC widely used sildenafil for treatment of
PAH, managing transient PAH during surgery, preparing
for cardiac transplantation and as a vasodilator drug for
haemodynamic study during cardiac catheterization.
According to the pharmacist, once both pharmaceutical
forms (tablets and powder papers) are available at this
hospital, the clinical staff is free to decide the prescription
(i.e. powder papers to adults with swallowing difficulties
and tablets to older children).
During the period of evaluation, few patients used silde-
nafil at IECAC and HPC (see Additional file 1). Despite
sildenafil is also available at IECAC in both pharmaceuti-
cal forms, the powder papers are only dispensed by the
pharmacy to pediatric patients. According to the pharma-
cist, children who do not require manipulation of the
commercial form may receive tablets. All patients at HPC
received sildenafil tablets with no external manipulation.
Sildenafil powder papers quantification analyses
The results of the quantification of sildenafil in the pow-
der papers from two private pharmacies (A and B) and a
public hospital pharmacy (C) used in the reference hospi-
tals evaluated are shown in (see Additional file 2). TheBMC Research Notes 2009, 2:30 http://www.biomedcentral.com/1756-0500/2/30
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analysis showed that samples from A and B (58.5–89.3%)
were below the minimum amount required of sildenafil
(90–110%) whereas the public hospital pharmacy met
the proper quality criteria (see Additional file 2).
Discussion
The use of sildenafil is not well established in pulmonary
arterial hypertension (PAH) due to the lack of evidence
and poor methodologic quality studies. This situation is
partially explained by the low prevalence of the pathology
in the population and turn analyses about current prac-
tices in using this inhibitor of great interest. In Brazil, the
hospitals data are not organized and collecting informa-
tion is not an easy task. Thus surveys are difficult to carry
on as also involve the analyses and combination of partic-
ularly fragmented records with the professionals point of
view. In a developing world environment, this process
may be even more problematic as vastly under-resource
services and fully paper-based records that use different
notation patterns are also frequent. For example, despite
of obtaining all records on the use of sildenafil in the three
reference hospitals evaluated, it is not possible to guaran-
tee that the patients used all pills as this was not recorded
on the pharmacy notes.
The three hospitals evaluated in this work are the main
cardiologic care institutions at the state of Rio de Janeiro.
They perform most of the treatment of cardiologic dis-
eases in Rio de Janeiro. As most of the patients in use of
sildenafil for PAH are assisted by these three institutions
in this state, we suggested that the procedures observed in
this study may reflect the reality for all patients.
Although we did not look into patients notes for the
actual dose received by each patient, the protocol for
using sildenafil in at least one hospital (INC) recom-
mended a smaller dose (0.3 to 0.4 mg/kg/dose every 8
hours) than that described by some case reports (2 mg/kg/
dose every 6 hours) [3,4]. It is of current knowledge that
modifying a commercially available drug is always prob-
lematic. This modification may lead to increased toxicity,
undesirable side effects, decreased efficacy, poor patient
compliance due to medication taste and potential hazards
to health care workers. Furthermore, this practice does not
guarantee the right dose administration as errors may
occur in preparing and administering the doses whereas
the powder papers preparation are time-consuming, and
difficult to make.
Considering that the acceptable percentage of a specific
dose in a formulation is 90 to 110%, our data showed that
none of the powder papers prepared by the pharmacies
that were tested in this study would be considered appro-
priate in a quality control analysis, except by the public
hospital pharmacy. This study suggested that most of
patients who need treatment or diagnosis at these institu-
tions are possibly not receiving the proper sildenafil dose,
and it is difficult to predict the consequences of this prac-
tice for these patients. In addition it is possible to specu-
late that this practice is not only taking place in Rio de
Janeiro, but possibly in more developed countries.
Conclusion
Currently the use of sildenafil in children is affected by the
crushing-tablets practice that leads to dosage errors.
According to our results very few patients received the pre-
scribed dose at some of these reference hospitals in the
period analyzed. A trial was designed to compare the
sildenafil powder papers regularly used in these hospitals
with a sildenafil suspension developed following the
good practices requirements of a compounding formula-
tion, which provided good evidences for further studies in
this under researched area.
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The use of sildenafil in three main reference hospitals of Rio de Janeiro 
– Instituto Nacional de Cardiologia (INC), Instituto Estadual de 
Cardiologia Aloysio de Castro (IECAC), and Hospital Pro-Cardíaco 
(HPC) – during April, 2008. Data provided represent the amount of 
sildenafil (in mg) used in three hospitals in Rio de Janeiro during April, 
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Quantification analysis results (%) of the sildenafil powder papers 
from two private pharmacies (A and B) and a public hospital phar-
macy (C) that are suppliers of the reference hospitals. The data pro-
vided represent the results of quantification analysis: the percentage of 
sildenafil present in the powder papers compounded by two private phar-
macies (A and B) and a public hospital pharmacy (C) that are suppliers 
of the reference hospitals.
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